Chemplast Sanmar Shares Decline 5% Takes as Massive ₹898 Cr S-PVC Impairment Triggers ₹1,003 Cr Loss

Synopsis: Chemplast Sanmar Limited reported a standalone net loss of Rs. 1,003 crore for FY26 on May 25, 2026, dominated by a Rs. 898 crore exceptional impairment on its S-PVC subsidiary. More intriguingly, the Board simultaneously constituted a committee of Independent Directors to evaluate “reorganisation and M&A opportunities” , a signal that could define the company’s next chapter.

In a regulatory filing submitted on May 25, 2026, Chemplast Sanmar Limited disclosed its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory audit was conducted by BSR & Co. LLP, Chartered Accountants, Chennai, with an unmodified opinion confirming the figures are a fair representation of the company’s financial position.

Shares of Chemplast Sanmar Limited declined over 5% in Tuesday’s session to Rs. 238 after witnessing heavy selling pressure through the morning trade. The stock opened sharply higher at Rs. 252 and touched an intraday high of Rs. 254.90 before slipping to a low of Rs. 235.04. Trading volumes remained active with turnover crossing Rs. 17 crore by mid-session. The specialty chemicals company continues to face pressure amid weak earnings visibility, with the stock down nearly 46% over the past one year despite showing some short-term recovery from its March 2026 lows.

On a standalone basis, Chemplast Sanmar reported revenue from operations of Rs. 2,170 crore for FY26, down from Rs. 2,388 crore in FY25, a decline of approximately 9%. Loss before exceptional items and tax stood at Rs. 141 crore versus a loss of Rs. 112 crore in FY25, indicating that the underlying specialty chemicals business remains under pressure from elevated raw material costs, PVC price weakness, and subdued demand.

However, the number that dominates the FY26 financial narrative is an exceptional item of Rs. 898 crore a full impairment provision on the company’s investment in its wholly-owned subsidiary Chemplast Cuddalore Vinyls Limited (CCVL), which manufactures Suspension PVC (S-PVC). The standalone net loss after tax for FY26 came in at Rs. 1,003 crore, with basic and diluted EPS at a loss of Rs. 63.46 per share.

Why Rs. 898 Crore Was Written Off

The impairment of the CCVL investment is explained in the company’s notes and is rooted in a confluence of adverse policy and market developments. The expected anti-dumping duty on S-PVC imports was not notified, effectively removing a critical protective mechanism for domestic manufacturers. 

Simultaneously, customs duty on S-PVC imports was removed, opening the door to a flood of low-priced imports. West-Asia supply chain disruptions further added raw material price volatility. The company commissioned an independent valuer to assess CCVL’s carrying value against revised cash flow projections, and the outcome was the full Rs. 898 crore impairment charge presented as an exceptional item rather than an operating loss, given its one-time, regulatory-driven nature.

At the consolidated level, the impact is partially different. CCVL, as a subsidiary, recorded Rs. 149.92 crore in exceptional items comprising provisions for onerous procurement contracts (Rs. 113.77 crore) and a writedown of raw material inventory (Rs. 36.15 crore) arising from non-cancellable procurement arrangements entered into in March 2026 amid the West-Asia crisis. Consolidated PAT for FY26 stood at a loss of Rs. 280 crore, on consolidated revenue from operations of Rs. 4,224 crore.

True to the difficult year, the Board has not recommended any dividend on equity shares for FY26. The 42nd Annual General Meeting is scheduled for August 7, 2026, to be conducted via video conference.

The most consequential development in the filing, however, is not the financial results but the constitution of a Committee of Independent Directors. The Board has formed a three-member committee of Independent Directors tasked with examining the company’s strategic priorities with a view to enhancing long-term stakeholder value. 

The committee is explicitly empowered to evaluate potential reorganisation and M&A opportunities, and may engage external advisors in this process. Findings will be tabled to the full Board for review and decision-making. This is a meaningful governance signal an independent committee with an explicit M&A mandate suggests the Board is actively considering structural options, which could range from asset sales, subsidiary restructuring, or a broader strategic transaction.

The Board also appointed Mr. V S Radhakrishnan as Non-Executive and Non-Independent Director, replacing Mr. Sumit Maheshwari. Mr. Radhakrishnan brings over 30 years of banking experience from the State Bank of India, including a stint as Deputy Managing Director, and has previously served on the boards of Yes Bank, Tata Capital, and Tube Investments of India.

Company Overview

Chemplast Sanmar Limited, incorporated in 1985 and headquartered in Chennai, is part of the Sanmar Group. The company is a specialty and commodity chemicals manufacturer, operating across two segments: Specialty Chemicals (including custom synthesis, paste PVC, and specialty pastes) and Commodity Chemicals through its subsidiary Chemplast Cuddalore Vinyls Limited. Listed on NSE and BSE, the company serves customers across pharmaceuticals, agrochemicals, and industrial sectors.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Chemplast Sanmar Shares Decline 5% Takes as Massive ₹898 Cr S-PVC Impairment Triggers ₹1,003 Cr Loss appeared first on Trade Brains.